Loading...
XNAS
ABEO
Market cap252mUSD
Oct 20, Last price  
4.60USD
1D
-0.45%
1Q
-32.47%
Jan 2017
-96.36%
Name

Abeona Therapeutics Inc

Chart & performance

D1W1MN
XNAS:ABEO chart
P/E
3.70
P/S
45.20
EPS
1.24
Vol. 1Y
53.57%
Shs. 5Y
77.94%
Rev. 5Y
-10.26%
Div Yld LY
—
Div Yld TTM
—
Revenues
6m
057,000291,000352,000481,0001,848,0004,404,0002,042,000925,0001,040,000889,000837,0002,998,000010,000,0003,000,0001,414,0003,500,00005,820,000
Net income
71m
P
-12,874,000-21,744,000-31,431,000-17,340,000-7,537,000-2,532,000-10,532,0004,449,000-26,778,000-14,526,000-21,873,000-27,319,000-56,671,000-76,282,000-84,234,000-84,936,000-39,696,000-54,188,000-63,734,00071,183,000
CFO
-76m
L+36.26%
-1,958,0004,843,000-6,560,000-2,248,000-6,860,000-7,609,000-3,955,0001,000-1,611,000-10,423,000-13,014,000-22,935,000-39,111,000-62,820,000-35,019,000-65,665,000-43,483,000-37,009,000-56,015,000-76,326,000
Dividend
Mar 31, 20000.593 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.

Key people

Michael Amoroso
Chairman of the Board · since 2021
Vishwas Seshadri
President, Chief Executive Officer, Director · since 2021
Joseph Vazzano
Chief Financial Officer · since 2022
Brendan O Malley
General Counsel · since 2021
Leila Alland
Independent Director · since 2021
Mark Alvino
Independent Director · since 2021
Faith Charles
Independent Director · since 2021
Eric Crombez
Independent Director · since 2024
Christine Silverstein
Independent Director · since 2020
Donald Wuchterl
Independent Director · since 2021
Bernhardt Zeiher
Independent Director · since 2024
URL
https://abeonatherapeutics.com/
IPO date
Sep 19, 1980
Employees
57
Domiciled in
US
Incorporated in
US
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
4848 Lemmon Avenue
Suite 517
Dallas, TX 75219
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT